Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

September 19, 2024

Study Completion Date

November 18, 2024

Conditions
Lower Eyelid Steatoblepharon
Interventions
DRUG

POLAT-001

Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.

DRUG

Placebo

Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.

Trial Locations (3)

33146

Skin Associates of South Florida, Coral Gables

78660

Austin Institute for Clinical Research, Pflugerville

92663

Medical Associates, Inc., Newport Beach

Sponsors
All Listed Sponsors
lead

Peregrine Ophthalmic

INDUSTRY

NCT05935527 - Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon | Biotech Hunter | Biotech Hunter